Rice Synthesis X Center (SynthX)
The mission of the Rice Synthesis X Center (SynthX) is to drive transformative advances in cancer therapy and biomedical technology by harnessing innovations in molecular and materials synthesis. By integrating expertise in organic chemistry, chemical biology, nanomaterial engineering, and artificial intelligence-enabled drug discovery, SynthX is creating a powerful platform for translating fundamental chemical innovation into clinically impactful solutions. Established in 2024, the Center works closely with leading cancer programs across the Texas Medical Center (TMC)—the largest medical complex in the world—to accelerate the development of next-generation therapeutics and diagnostic technologies that address some of the most pressing challenges in cancer treatment.
At the core of SynthX’s impact is its ability to design and construct molecules and functional materials with unprecedented precision across multiple length scales. Leveraging cutting-edge synthetic methodologies and AI-assisted design, SynthX researchers can engineer macromolecular and supramolecular systems with atomic-level control. This capability allows the Center to move beyond the constraints of natural biological processes and create entirely new classes of therapeutic agents, imaging probes, and biomaterials. These advances are enabling innovative strategies to detect, monitor, and treat disease, ultimately bridging the gap between chemical discovery and patient care.
SynthX also serves as a hub for interdisciplinary collaboration and knowledge exchange. Through signature events such as the “Unlocking the Clinical Potential of Chemical Innovation” Workshops, the Synthetic Innovations Towards a Cure for Cancer Conference, the SynthX/Duncan Cancer Center Retreat, and the Next-Generation Computational Bio-Imaging Conference, the center fosters active engagement among chemists, engineers, clinicians, and computational scientists. These events not only catalyze new collaborations but also provide invaluable exposure for early-career researchers, helping train the next generation of scientists who will lead future advances in translational medicine.
In just a short time since its establishment in 2024, SynthX has already demonstrated significant impact by securing more than $24 million in collaborative research funding, including major awards from the U.S. Department of Defense and the National Institutes of Health. Among its most ambitious initiatives is the ARPA-H–supported project VISTA-LYMPH: Visual Imaging System for Tracing and Analyzing Lymphatics with Photoacoustics, an $18 million program aimed at transforming how lymphatic diseases are diagnosed and monitored. By developing both blood-based biomarkers and a non-invasive imaging platform capable of mapping lymphatic function in real time, this effort seeks to establish entirely new clinical capabilities for managing lymphatic disorders and improving patient outcomes. The close partnership between SynthX and the Baylor College of Medicine (BCM) Cancer Center has also led to the creation of Osteologics Therapeutics, a joint start-up dedicated to developing next-generation therapeutics that selectively target bone tissues. Osteologics is currently the only company in the United States focused specifically on precision drug delivery to the bone, addressing critical unmet needs in diseases such as bone metastasis and osteoporosis. The company is backed by the leading biotech venture group Curie.Bio, highlighting the strong translational potential of technologies emerging from the Rice-BCM collaboration.
By bringing together Rice scientists and clinicians from across the Texas Medical Center, the center creates a powerful ecosystem for innovation where discoveries in molecular design can rapidly evolve into therapeutic strategies and diagnostic technologies ready for clinical evaluation. Through this unique integration of chemistry, engineering, and medicine, SynthX is positioning Rice University and its partners at the forefront of a new era of precision therapeutics and translational chemical innovation.
Source: Han Xiao, SynthX Center: https://synthx.rice.edu/
Last updated: March 2026